Advances in High Grade Glioma Research

Topic Information

Dear Colleagues,

High-grade gliomas (HGGs), particularly glioblastoma, are among the most aggressive and lethal tumors of the central nervous system, challenging even advanced diagnostic and prognostic strategies.

These tumors grow masked behind a plethora of neurological signs, having systemic effects. Surgery is restricted to the neuroanatomical location, while the blood–brain barrier limits drug treatments. HGGs appear with distinct biological features, establishing a structural relationship within the nervous tissue. The immune distribution is diverse between samples and correlates with tumor cell phenotype in a spatial orientation.

Despite advances in personalized medicine, spatial biology, immunotherapy, and a high-precision ion beam approach, patient prognosis remains unfavorable, requiring urgent studies to understand brain tumor biology, polarization of the microenvironment, and systemic mechanisms.

The combination of diverse treatments and technologies holds promise for improving the prognosis of HGG. The present topic aims to collect ideas, hypotheses, and proofs to leverage the knowledge provided by multitargeted approaches, such as immune checkpoint inhibitors, vaccines, or CAR-T cells, combined with nanomedicine, tumor treating fields (TTFields), artificial intelligence, or radiomics inter-field.

Therefore, journal articles, reviews, letters, and communications related to the aforementioned topics are welcome.

Dr. Assunta Virtuoso
Dr. Agata Grazia D'Amico
Dr. Celeste Caruso Bavisotto
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Brain Sciences brainsci	2.8	5.6	2011	17.6 Days	CHF 2200	Submit
Neurology International neurolint	3.0	4.8	2009	21.5 Days	CHF 1800	Submit
NeuroSci neurosci	2.0	-	2020	23.3 Days	CHF 1200	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Brain Sciences Neurology International NeuroSci

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

46 pages, 1236 KB  

Open AccessReview

Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers

by Nirupama A. Sabnis, Luke C. Cooksey, Hareesh Jayakumar, Mariana Moguel Mendez, Ezek Mathew, Roland Max Petty, Amalendu Ranjan, Luis Colon-Perez, Rob Dickerman, Porunelloor A. Mathew and Bruce A. Bunnell

Brain Sci. 2026, 16(5), 487; https://doi.org/10.3390/brainsci16050487 - 30 Apr 2026

Viewed by 875

Abstract

Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web [...] Read more.

Glioblastoma (GB) remains the most aggressive primary brain malignancy, with the Stupp regimen persisting as the standard of care for nearly two decades despite poor survival outcomes. This review was synthesized by extensively reviewing and analyzing the literature from PubMed, Scopus, and Web of Science to evaluate the emerging promising therapeutic and diagnostic strategies for combating GB. Results indicate significant progress in molecularly targeted therapies, biomimetic nanocarriers, and advanced radiotherapy. While immunotherapeutic approaches, such as checkpoint inhibitors and vaccines, show variable clinical success, the integration of bioinformatics and machine learning has significantly enhanced treatment response prediction. Furthermore, advances in radiomics and molecular imaging have improved the differentiation between true tumor progression and pseudoprogression, potentially reducing invasive diagnostic requirements. Additionally, other emerging and investigational adjuvant therapeutic approaches have shown promise. We conclude that, while multimodal strategies integrating molecular and computational approaches offer a path toward personalized GB management, significant barriers—namely tumor heterogeneity and the blood–brain barrier—persist. Future research must prioritize precision-based combinatorial models to successfully translate these preclinical advancements into improved clinical outcomes for patients. Full article

(This article belongs to the Topic Advances in High Grade Glioma Research)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1